logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Can we measure prior Postmenopausal estrogen/progestin use : The Postmenopausal Estrogen/Progestin Interventions Trial.

    Article - En anglais

    Fulltext.

    The objective of this study was to assess : 1) the accuracy of a single self-report question about postmenopausal estrogen use ; and 2) the performance and repeated measures agreement of a standardized hormone use interview.

    Women (n=863) in the Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) completed a self-report baseline questionnaire (BQ) at enrollment and a History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos).

    A subsample of 101 women completed a second HHU interview 3 years later (HHU3yrs).

    As determined by the HHU3mos, 479 (56%) of women had ever used postmenopausal estrogen and 261 (30%) had ever used postmenopausal progestin.

    The mean number of years since last estrogen or progestin use was 2.2 and 1.3 years, respectively.

    Overall, there was 95% agreement between self-reported estrogen use on the BQ and the HHU3mos (kappa=0.91).

    Using the HHU3mos as the criterion standard, the BQ misclassified 2.3% of women as false positives and 6.3% as false negatives.

    The average duration of estrogen use in the false-negative classifications was 1.9 years (range : 1-9 years).

    On the HHU3mos, 39.7% of participants could not recall at least one of the specific details of estrogen use (preparation, dose, route, or starting or stopping year) ; similar patterns of recall were found for progestin use.

    Factors associated with discordant reporting of ever-use of ERT (BQ vs. (...)

    Mots-clés Pascal : Oestrogène, Progestatif, Hormone stéroïde sexuelle, Chimiothérapie, Traitement substitutif, Autoévaluation, Rappel, Homme, Femelle, Ménopause, Méthodologie, Epidémiologie

    Mots-clés Pascal anglais : Estrogen, Progestagen, Sex steroid hormone, Chemotherapy, Replacement therapy, Self evaluation, Recall, Human, Female, Menopause, Methodology, Epidemiology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0007539

    Code Inist : 002B30A01A1. Création : 17/04/1998.